GlassScriptPhysician profile
Brian Paul Dickover
NPI 1083699904
$12,471.12
in general payments reported to CMS, 2019-2025
31 companies · $4,676 in 2025
The $4,676 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $123 · 2021: $293 · 2022: $304 · 2023: $4,586 · 2024: $2,213 · 2025: $4,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,474 · Travel and Lodging: $3,511 · Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,473.68 |
| Travel and Lodging | $3,510.85 |
| Food and Beverage | $2,491.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,771.52 | 2022-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Inspire Medical Systems, INC. | $2,123.43 | 2023-2025 | Inspire |
| Olympus Corporation of The Americas | $1,311.15 | 2024 | Single Use Suction Valve (Sterile) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.10 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $280.88 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Avadel Cns Pharmaceuticals, LLC | $198.30 | 2024-2025 | Lumryz |
| Pulmonx Corporation | $163.54 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Abbvie INC. | $132.72 | 2023-2025 | Avycaz, Teflaro, Dalvance |
| Mallinckrodt Hospital Products INC. | $128.69 | 2023 | Acthar |
| Astellas Pharma US INC | $126.43 | 2019-2021 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Penumbra, INC. | $117.31 | 2023 | Indigo System |
| Glaxosmithkline, LLC. | $101.31 | 2020-2024 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Mylan Specialty L.P. | $83.69 | 2022-2024 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $78.92 | 2023-2024 | |
| Harmony Biosciences LLC | $53.95 | 2024 | |
| Baxter Healthcare | $32.69 | 2023 | Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $28.81 | 2024 | Sunosi |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Zerbaxa |
| Grifols USA, LLC | $23.43 | 2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $21.10 | 2019 | |
| Genzyme Corporation | $19.78 | 2024 | |
| Philips North America LLC | $18.20 | 2023 | |
| Insmed, INC. | $17.39 | 2024 | Arikayce |
| Medtronic, INC. | $16.29 | 2022 | |
| Olympus America INC. | $16.04 | 2023 | Evis Exera II Ultrasonic Bronchofibervideoscope, Oes Bronchofiberscope |
| Verona Pharma, INC. | $15.81 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $14.86 | 2019 | |
| Amgen INC. | $11.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dickover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.